← Back to Clinical Trials
Recruiting NCT07346716

NCT07346716 Medicines in Breast Milk and Estimated Infant Exposure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07346716
Status Recruiting
Phase
Sponsor University Hospital Bispebjerg and Frederiksberg
Condition Breastfeeding
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2024-12-20
Primary Completion 2028-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Prescription Drugs

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2024-12-20 with a primary completion date of 2028-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The MedMilk (Medication concentrations in human Milk) study investigates how selected medicines taken by breastfeeding women are transferred into human milk and whether this may affect the breastfed child. The study includes breastfeeding women who are already using prescription or over-the-counter medicines as part of their usual care. Participants provide samples of breast milk and urine and complete a questionnaire about maternal and infant health. The collected data will be used to quantify medicine concentrations in milk and estimate the relative infant dose. The study aims to contribute new data to support safer prescribing and more informed counselling during breastfeeding

Eligibility Criteria

Inclusion Criteria: * Lactating women aged ≥18 years * Current use of one or more prescription or over-the-counter (classified within the ATC system) drugs * Able and willing to provide written informed consent Exclusion Criteria: * Current pregnancy during sample collection * Known and clinically significant pharmacokinetic drug-drug interactions at the time of sampling

Contact & Investigator

Central Contact

Ditte Resendal Gotfredsen, MD

✉ ditte.resendal.gotfredsen@regionh.dk

📞 +4521472051

Principal Investigator

Jon Traerup Andersen, Professor, MD, PhD

PRINCIPAL INVESTIGATOR

Department of Clinical Pharmacology, Bispbjeg and Frederiksberg Hospital

Frequently Asked Questions

Who can join the NCT07346716 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Breastfeeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07346716 currently recruiting?

Yes, NCT07346716 is actively recruiting participants. Contact the research team at ditte.resendal.gotfredsen@regionh.dk for enrollment information.

Where is the NCT07346716 trial being conducted?

This trial is being conducted at Copenhagen, Denmark, Copenhagen, Denmark, Herlev, Denmark.

Who is sponsoring the NCT07346716 clinical trial?

NCT07346716 is sponsored by University Hospital Bispebjerg and Frederiksberg. The principal investigator is Jon Traerup Andersen, Professor, MD, PhD at Department of Clinical Pharmacology, Bispbjeg and Frederiksberg Hospital. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology